FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

| 1. Name and Address Olivo Alicia C | 1 0 | | 2. Issuer Name and Ticker or Trading Symbol <u>NEOGENOMICS INC</u> [NEO] | | tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify | | |
|---------------------------------------|-----------------------------------|-------|---|----------------|--|----------------------|--|
| (Last) 9490 NEOGENOM | (First) (Middle) OGENOMICS WAY | | 3. Date of Earliest Transaction (Month/Day/Year) 09/01/2024 | Α | below) General Co | below) punsel | |
| (Street) FORT MYERS | FL | 33912 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indivi X | dual or Joint/Group Filing (Form filed by One Repo Form filed by More than | rting Person | |
| (City) | (State) | (Zip) | | | . e nea by wore than | Sile reperang Person | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transac Code (Ir 8) | | | Following Rep | | Securities Beneficially Owned | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--|---|---------------------------------|---|----------------------|---------------------|-------------------|----------------------------------|---|---|
| | | | Code | v | Amount | Amount (A) or Price | | (Instr. 3 and 4) | | (1130. 4) |
| Common Stock | 09/01/2024 | | F | | 1,666 ⁽¹⁾ | D | \$ <mark>0</mark> | 42,147 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|---|--|---|---|---|--|-----|--|--------------------|--|-------------------------------------|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| Stock Option (Right to Buy) | \$19.12 | | | | | | | (2) | 09/30/2026 | Common Stock | 1,046 | | 1,046 | D | |
| Stock Option (Right to Buy) | \$27.34 | | | | | | | (3) | 05/01/2027 | Common Stock | 1,024 | | 1,024 | D | |
| Stock Option (Right to Buy) | \$48.99 | | | | | | | (4) | 05/01/2028 | Common Stock | 516 | | 516 | D | |
| Stock Option (Right to Buy) | \$46.1 | | | | | | | (5) | 08/01/2028 | Common Stock | 1,117 | | 1,117 | D | |
| Stock Option (Right to Buy) | \$9.45 | | | | | | | (6) | 05/01/2029 | Common Stock | 22,222 | | 22,222 | D | |
| Stock Option (Right to Buy) | \$10.05 | | | | | | | (7) | 09/01/2029 | Common Stock | 55,332 | | 55,332 | D | |
| Stock Option (Right to Buy) | \$19.65 | | | | | | | (8) | 05/11/2030 | Common Stock | 36,508 | | 36,508 | D | |
| Performance Stock Unit | \$0 | | | | | | | 05/11/2026 ⁽⁹⁾ | (10) | Common Stock | 19,508 | | 19,508 | D | |
| Restricted Stock Unit | \$0 | | | | | | | (11) | (10) | Common Stock | 13,006 | | 13,006 | D | |
| Stock Option (Right to Buy) | \$16.45 | | | | | | | (12) | 02/23/2034 | Common Stock | 42,344 | | 42,344 | D | |
| Performance Stock Unit | \$0 | | | | | | | 02/23/2027 ⁽¹³⁾ | (10) | Common Stock | 25,330 | | 25,330 | D | |
| Restricted Stock Unit | \$0 | | | | | | | (14) | (10) | Common Stock | 25,329 | | 25,329 | D | |

Explanation of Responses:

1. Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the September 1, 2024 vesting of restricted stock.

2. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.

3. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.

4. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.

5. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.

6. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.

7. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.

8. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.

9. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.

10. Once vested, the shares of common stock are not subject to expiration.

11. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.

12. On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.

13. On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. S0% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

14. On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.

Remarks:

/s/ Alicia C. Olivo

** Signature of Reporting Person

09/04/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.